APMD.US Apnimed, Inc. Common Stock
- Market cap
- USD 704M
- P/E
- 2.3x
- P/B
- 4.40x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is APMD.US undervalued?
Graham numberAPMD.US trades 32.3% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Apnimed, Inc. Common Stock fundamental analysis
No fundamental analysis for Apnimed, Inc. Common Stock yet.
Apnimed, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Apnimed, Inc. Common Stock
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Full company profileApnimed, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Apnimed, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 8.01M | 38.5M | 194M |
| Gross Profit | 4.64M | 31.8M | 187M |
| Operating Income | -114M | -53.8M | 113M |
| EBITDA | -114M | -53.8M | 113M |
| Net Income | -111M | -932K | 393M |
| EPS | -2.79 | -0.02 | 9.86 |
| Balance Sheet | |||
| Total Assets | 109M | 72.9M | 195M |
| Total Liabilities | 358M | 446M | 372M |
| Shareholders' Equity | -249M | -373M | -176M |
| Cash & Short-term Investments | 68.4M | 41.9M | 173M |
| Cash Flow | |||
| Operating Cash Flow | -110M | -77.8M | -75.9M |
| Capital Expenditure | 70.0K | 0.00 | 0.00 |
| Free Cash Flow | -110M | -77.8M | -76.5M |
| Ratios | |||
| ROA | -101.9% | -1.3% | 200.9% |
| Net Profit Margin | -1,389.2% | -2.4% | 202.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Apnimed, Inc. Common Stock dividends
Apnimed, Inc. Common Stock has not paid dividends in the last 2 fiscal years.
Who owns Apnimed, Inc. Common Stock
- Insiders 43.14%
- Institutions 56.86%
- Public & others 0.00%
- Shares outstanding 41.6M
- Free float 21.7M
Top funds holding APMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Columbia Seligman Tech & Info A | 7.44M | 17.88% | +3.40% | Sep 2026 |
| PGIM Jennison Health Sciences Z | 559K | 1.34% | +14.36% | Sep 2026 |
| JPMorgan Small Cap Growth A | 495K | 1.19% | 0.00% | Sep 2026 |
| Highland Global Allocation A | 405K | 0.97% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 398K | 0.96% | +544.95% | Sep 2026 |
| iShares Russell 2000 ETF | 315K | 0.76% | 0.00% | Oct 2026 |
| AB Small Cap Growth A | 291K | 0.70% | -2.81% | Sep 2026 |
| abrdn Healthcare Opportunities | 239K | 0.57% | +36.56% | Sep 2026 |
| abrdn Healthcare Investors | 225K | 0.54% | 0.00% | Sep 2026 |
| Biotech Growth Ord | 208K | 0.50% | 0.00% | Jul 2026 |
| abrdn Life Sciences Investors | 177K | 0.43% | +57.76% | Sep 2026 |
| abrdn World Healthcare | 171K | 0.41% | +51.89% | Sep 2026 |
| JPMorgan Small Cap Blend A | 157K | 0.38% | 0.00% | Sep 2026 |
| Fidelity Contrafund | 95.9K | 0.23% | -24.43% | Sep 2026 |
| Principal SmallCap Growth I Instl | 92.9K | 0.22% | +0.98% | Sep 2026 |
| Fidelity Select Biotechnology | 92.4K | 0.22% | 0.00% | Aug 2026 |
| JPMorgan Small Cap Value I | 92.2K | 0.22% | 0.00% | Sep 2026 |
| Multi-Manager Small Cap Eq Strat Inst | 78.1K | 0.19% | 0.00% | Sep 2026 |
| JPMorgan US Small Company L | 77.6K | 0.19% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 71.5K | 0.17% | +804.51% | Sep 2026 |
Apnimed, Inc. Common Stock company profile
- Company name
- Apnimed, Inc. Common Stock
- Ticker
- APMD.US
- Exchange
- USA Stocks
- Listed since
- Jul 31, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 81
- Fiscal year end
- December
- Address
- 39 John F. Kennedy Street, Cambridge, MA, United States, 02138
- Phone
- 617 500 8880
- Website
- apnimed.com
About Apnimed, Inc. Common Stock
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Apnimed, Inc. Common Stock management
10- Mr. Kevin Robert LindCEO & Director · born 1976
- Dr. Lawrence G. Miller M.D., M.P.H.Founder & Vice Chair of the Board · born 1954
- Mr. Dennis Patrick Molnar M.B.A.President & COO · born 1969
- Dr. Luigi Taranto Montemurro M.D.Co-Founder & Chief Scientific Officer · born 1979
- Mr. Michael B. KellyChief Financial Officer · born 1975
- Ms. Leila SylvainSenior Manager of Administration
- Mr. Steven W. Spector J.D.Chief Legal Officer & Head of Corporate Affairs · born 1965
- Ms. Jennifer PattersonSenior Vice President of Human Resources
- Dr. John W. Cronin M.D.Chief Medical Officer · born 1968
- Dr. Sean M. Johnston M.B.A., Ph.D.Consulting Head of CMC · born 1958